Saturday, May 30, 2026
In Detail Full day, Saturday, May 30, 2026, Timezone: America/Chicago
OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
UnitedHealthcare to nix nearly two thirds of pediatric prior auths
fiercehealthcare - UnitedHealthcare is set to eliminate close to two-thirds of pediatric prior authorization requirements by the end of the year.
AI Summary: UnitedHealthcare announced a major rollback of pediatric prior authorization requirements, eliminating roughly two‑thirds of those rules to reduce administrative burden and speed care for children. The move aims to ease clinician frustration and patient delays, while insurers and providers brace for workflow and cost‑management implications.
Blue Moon 2026: An extremely rare micromoon rises tonight
livescience - A rare Blue Moon, the second full moon in May, will also be a "micromoon" near its farthest point from Earth.
AI Summary: A rare "blue micromoon" peaked in late May 2026: a second full moon in a calendar month that coincided with a slightly smaller apparent lunar size due to perigee/apogee timing. Skywatchers were urged to look up for this quirky celestial double‑feature — same moon, different calendar trickery, minimal lunar mood swings guaranteed.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
Not just ovaries—new name for PCOS reflects the condition's multisystem nature
medicalxpress - An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In actuality, the condition is a broader metabolic and hormon…
AI Summary: Medical experts announced a name change for polycystic ovary syndrome to better reflect its multisystem effects rather than framing it solely as an ovarian disorder. The update aims to reduce stigma, encourage holistic management of metabolic and psychological comorbidities, and align terminology with current scientific understanding of the condition.
FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN
oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]
AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.
- ASCO 2026: ADC education, efficacy signals, and ocular toxicity (4)
- Decnupaz approval reshapes BPDCN treatment landscape (4)
- Real-world ADC safety: infection risks and rechallenge questions (3)
ASCO 2026: ADC education, efficacy signals, and ocular toxicity
Decnupaz approval reshapes BPDCN treatment landscape
Real-world ADC safety: infection risks and rechallenge questions
MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
- ASCO social media: expert reactions and highlights (4)
- MajesTEC‑9: Teclistamab outperforms PVd/Kd (4)
- Other BCMA and novel myeloma immunotherapies at ASCO (3)
- All Other Stories
ASCO social media: expert reactions and highlights
MajesTEC‑9: Teclistamab outperforms PVd/Kd
Other BCMA and novel myeloma immunotherapies at ASCO
All Other Stories
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, CDC, Behavioral Health, Gene Therapy and look for the RSS link.
StackHealth Time Machine
More StackHealth